Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
7-deaza-dG-CE Phosphoramidite
7-deaza-dG-CE Phosphoramidite
Glen Research
| Catalogue No. | Description | Pack Size | Price | Qty |
|
|---|---|---|---|---|---|
| 10-1021-02 | 7-deaza-dG-CE Phosphoramidite | 0.25g | £780.00£741.00Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1021-90 | 7-deaza-dG-CE Phosphoramidite | 100µmoles | £284.00£269.80Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1021-95 | 7-deaza-dG-CE Phosphoramidite | 50µmoles | £142.00£134.90Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
7-deaza-dG-CE Phosphoramidite
7-deaza-dG-CE Phosphoramidite
Glen Research
| 7-deaza-dG-CE Phosphoramidite |
Catalog Number: 10-1021-xx
Description: 7-deaza-dG-CE Phosphoramidite
| 5"-Dimethoxytrityl-N2-dimethylaminomethylidene-7-deaza-2"-deoxyGuanosine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite | ||
| Formula: C44H54N7O7P | M.W.: 823.93 | F.W.: 328.22 |
Diluent: Anhydrous Acetonitrile |
| Coupling: Standard coupling time.Add a maximum of 2 times when using I2 oxidation or use 0.5M CSO in anhydrous acetonitrile and 3 min. oxidation time. (See Glen Report-Vol.9, No.1, 1996,page 8.) |
| Deprotection: No changes needed from standard method recommended by synthesizer manufacturer. |
| Storage: Refrigerated storage, maximum of 2-8°C, dry |
| Stability in Solution: 3-5days |
STRUCTURE/ACTIVITY RELATIONSHIPThe following products are used to investigate the effect on theactivity of an oligonucleotide when key structural elements are changed. The7-deaza purine monomers lack groups critical for hydrogen bonding.7-Deaza-8-aza-A and 7-deaza-8-aza-G (PPG) monomers are isomers of A and G andhave similar electron density. Their presence in oligos is slightly stabilizingrelative to A and G. Unlike G, PPG does not lead to aggregation and G-richoligos can be easily prepared and isolated. 5’-Fluorescein oligos with PPG atthe 5’-terminus are much less quenched than the equivalent G oligos. As a purineanalogue of Thymidine, 7-deaza-2’-deoxyXanthosine (7-deaza-dX) promises to haveinteresting effects on DNA structure of triplexes. 7-Deaza-dX also forms anon-standard base pair with a 2,4-diaminopyrimidine nucleoside analogue.Standard nucleobases have an unshared pair of electrons that project into theminor groove of duplex DNA. Enzymes that interact with DNA, polymerases, reversetranscriptases, restriction enzymes, etc., may use a hydrogen bond donatinggroup to contact the hydrogen bond acceptor in the minor groove.3-Deaza-2’-deoxyadenosine is very interesting in that it maintains the abilityfor regular Watson-Crick hydrogen bonding to T but is lacking the electron pairat the 3-position normally provided by N3. | |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
7-deaza-dG-CE Phosphoramidite
7-deaza-dG-CE Phosphoramidite
Glen Research
MSDS
Glen Report 9.1 (Oxidation with CSO): NON-AQUEOUS OXIDATION WITH 10-CAMPHORSULFONYL-OXAZIRIDINE
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
7-deaza-dG-CE Phosphoramidite
7-deaza-dG-CE Phosphoramidite
Glen Research
Frequently Asked Technical Question
QUESTION: What is a possible alterternative oxidizing solution to I2 ?
RESPONSE:In situations where you want to avoid the use of iodine containing oxidizing solutions, such as when using 7-deaza-dG, or when youwant to use a non aqueous oxidizing solution t-butyl hydroperoxide (TBHP) has been shown to work both for DNA (1) and RNA (2).
Reagents:
TBHP, anhydrous, 5-6M solution in decane (Aldrich 41,666-5)
Methylene chloride
For DNA small scale: 1.1 M TBHP in Methylene Chloride, 0.8 min oxidation (1)
For large scale RNA synthesis: 37ml TBHP solution 63ml Methylene Chloride (approx. 2M), 6 min oxidation (2)
Mix reagents fresh prior to use,oxidizing solution only stable for a few days on synthesizer.
REFERENCE(S):1.Hayakawa, Y., et al., JACS, 1990, 112, 1691.2.Sproat, B., et al., Nucleosides & Nucleotides, 1995, 14, 255.
QUESTION: How can you prevent oxidative damage of 7-deaza-dG during oligonucleotide synthesis?
RESPONSE:Non Aqueous Oxidation Using 10-Camphorsulfonyl-Oxaziridine
Solutions of enantiomers of 10-camphorsulfonyl-oxaziridine in acetonitrile can be used for the non aqueous oxidation of phosphite triesters to phosphate triesters in oligonucleotide synthesis.This is especially helpful in the synthesis of oligonucleotides containing 7-deaza-dG which is susceptible to damage during the standard I2 catalyzed oxidation step.
It was found that a 0.5 M solution of (1S)-( )-(10-camphorsulfonyl)- oxaziridine in acetonitrile (0.5M CSO) was an effective oxidizer for DNA synthesis.Oxidation time course studies demonstrated that a 3 minute oxidation wait step was sufficient to completely oxidize the phosphite triester to the acid stable phosphate triester.A mixed base oligo synthesized using 0.5M CSO and a 3 min. oxidation wait was indistinguishable by HPLC analysis from the same oligo synthesized using 0.02M I2 oxidizer.Additionally oxidation using 0.5M CSO resulted in no distinguishable modification of the bases as determined from base composition analysis of the enzyme digested oligos.When 0.5M CSO was used for the oxidation in the synthesis of an oligo containing multiple 7-deaza-dG"s no evidence of damage to the oligo was detected when the crude oligo was analyzed by RP HPLC.Successful incorporation of 7-deaza-dG was verified by base composition analysis of the enzyme digested oligo.The peak corresponding to 7-deaza-dG, in the enzyme digested sample, comigrated with a nucleoside standard of 7-deaza-dG and had an identical spectrum.
The synthesis cycle used for the experiments using CSO oxidation was a modified sulfurization cycle on an ABI 392 synthesizer with a 3 minute oxidation wait step.The oxidizing solution can either be delivered from the standard oxidizer port (bottle 15) or in this case from the cleave reservoir (bottle 10).The oxidation step occurred prior to the capping step as in phosphorothioate synthesis.Presumably any synthesizer with a sulfurizing cycle can be used if the oxidation wait step is ³ 3 minutes.
Materials:
• (1S)-( )-(10-camphorsulfonyl)oxaziridine(Aldrich # 34,535-0)
•Anhydrous acetonitrile
•Disposable syringe (10-30 ml)
•Solvent resistant syringe filter (0.22-0.45 µ)
Procedure:
•Dissolve (1S)-( )-(10-camphorsulfonyl)oxaziridine in anhydrous acetonitrile (8.72 ml/g).This can be done using the disposable syringe in the same way as for dissolving amidites.
•When the oxidizer is completely dissolved take it up into the syringe, attach the syringe filter and filter into a bottle that fits onto the appropriate port on the synthesizer.
•Modify the sulfurization cycle on the synthesizer to include a 3 minute wait step subsequent to delivery of the oxidizer solution.
•Synthesize the oligo using CSO oxidation at each step in the synthesis.All other conditions are the same.
• Cleave and deprotect the oligo using standard conditions.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
7-deaza-dG-CE Phosphoramidite
7-deaza-dG-CE Phosphoramidite
Glen Research
EXTINCTION DATA
| Item | Nucleoside | λMax-1 | Emax-1 | λMax-2 | Emax-2 | E260 |
| (nm) | (ml/µmole) | nm | (ml/µmole) | (ml/µmole) | ||
| 10-1021 | 7-deaza-dG | 259 | 12.6 | 12.6 |
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1021-02 | 0.25grams | .25grams | 3.03 | 87.67 | 52.6 | 32.88 | 23.91 | 17.53 | 4.38 |
| 10-1021-90 | 100µmoles | .082grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| 10-1021-95 | 50µmoles | .041grams | .5 | 3.33 | 2 | 1.25 | .91 | .67 | .17 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1021-02 | 0.25grams | .25grams | 4.53 | .07 | 84.2 | 52.63 | 38.27 | 5.26 | |
| 10-1021-90 | 100µmoles | .082grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
| 10-1021-95 | 50µmoles | .041grams | .75 | .07 | 8.6 | 5.38 | 3.91 | .54 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1021-02 | 0.25grams | .25grams | 4.53 | .07 | 85.8 | 53.63 | 39 | ||
| 10-1021-90 | 100µmoles | .082grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 | ||
| 10-1021-95 | 50µmoles | .041grams | .75 | .07 | 10.2 | 6.38 | 4.64 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
AthensResearch&Technology公司位于美国乔治亚州雅典市，从1986年以来一直致力于纯化高纯度，高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白，血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来，世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。我们提供优质，可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务，AthensResearch&Technology公司能够根据您的项目要求提供无与伦比的试剂。
公司主要产品：一、凝血因子相关系列产品：包括多款从人血浆、血小板中分离纯化的凝血因子相关蛋白。二、酶及抑制剂系列产品：包括多款从人血浆、红细胞分离纯化的a-抗糜蛋白酶、a1/2抗胰蛋白酶、抗凝血酶、C1酯酶抑制因子、Calpain-1等酶及其抑制剂产品。三、免疫球蛋白系列产品：包括多款从人血浆、骨髓瘤、初乳以及狗和小鼠血浆中分离纯化的免疫球蛋白产品。四、脂蛋白及载脂蛋白系列产品：包括包括多款从人血浆中分离纯化的载脂蛋白及脂蛋白（高密度、中等密度、低密度、极低密度脂蛋白）产品。五、低内毒素蛋白系列产品：包括多款适宜于细胞培养的低内毒素脂蛋白、免疫球蛋白及转铁蛋白产品。六、乳蛋白系列产品：包括从人乳中分离纯化的乳白蛋白、乳铁传递蛋白及分泌型免疫球蛋白A。七、中性粒细胞源蛋白系列产品：包括多款纯化分离自人中性粒细胞的Azurocidin 、CathepsinG及Lactoferrin等蛋白产品。八、血小板相关系列产品：包括纯化分离自人血小板的血小板因子4及凝血酶致敏蛋白。九、转铁蛋白及脱铁转铁蛋白（APOTRANSFERRINS）系列产品：包括多款纯化分离自人、大小鼠、狗及食蟹猴血浆中的转铁蛋白/脱铁转铁蛋白，可应用于细胞或组织培养。十、抗体系列产品：包括多款兔、大鼠、羊源的多克隆抗体产品。
ebiomall.com
